Related Experiment Videos
The psychomotor development of full term infants whose mothers were treated with glucocorticosteroids during
Insights
Antenatal Betamethasone treatment did not impact infant development. This study found no significant differences in Development Quotient (D.Q.) scores between infants exposed to Glucocorticosteroids and a control group.
Area of Science:
- Neonatal development
- Maternal-fetal medicine
- Pediatric neurology
Background:
- Antenatal corticosteroid therapy, such as Betamethasone, is used to accelerate fetal lung maturation.
- Potential neurodevelopmental effects of antenatal Glucocorticosteroids require thorough investigation.
Purpose of the Study:
- To evaluate the psychological and motor development of infants exposed antenatally to Betamethasone.
- To compare the Development Quotient (D.Q.) of treated infants with a control group.
Main Methods:
- Development Quotient (D.Q.) assessment was performed on 48 full-term infants (12-24 months) treated antenatally with Betamethasone.
- A control group of 100 age-matched, healthy full-term infants was used for comparison.
- Infant characteristics including gestational age, birth weight, Apgar scores, and delivery methods were analyzed.
Main Results:
- No statistically significant differences in D.Q. scores were observed between the Betamethasone-exposed group and the control group.
- While groups differed in gestational age, key perinatal factors like birth weight and Apgar scores were comparable.
- The study indicates no adverse effects on infant development from antenatal Glucocorticosteroid exposure.
Conclusions:
- Antenatal treatment with Glucocorticosteroids (Betamethasone) in the second and third trimesters appears safe regarding infant psychological and motor development.
- Findings support the use of antenatal corticosteroids for pulmonary maturity without compromising neurodevelopmental outcomes.
- Further long-term studies may provide additional insights into developmental trajectories.
Abstract:
The Development Quotient (D.Q.) was tested in 48 full term infants at the ages of 12-24 months who had been treated antenatally with Betamethasone to hasten pulmonary maturity. The results were compared with a control group of 100 normal full term infants of the same age. Although the two groups differed with respect to gestational age, there were no differences in birth weight, Apgar score and method of delivery between them. The results of the D.Q. evaluation showed no significant difference between the two groups. The assumption is made, therefore, that antenatal treatment with Glucocorticosteroids in the second and third trimester does not adversely affect the infant's psychological and motor development.